The blood system is multi-scale, from the organism to the organs to cells to intracellular signaling pathways to macromolecule interactions. Blood consists of circulating cells, cellular fragments (platelets and microparticles), and plasma macromolecules. Blood cells and their fragments result from a highly-ordered process, hematopoiesis. Definitive hematopoiesis occurs in the bone marrow, where pluripotential stem cells give rise to multiple lineages of highly specialized cells. Highly-productive and continuously regenerative, hematopoiesis requires a microenvironment of mesenchymal cells and blood vessels. A Systems Biology Approach to Blood is divided into three main sections: basic components, physiological processes, and clinical applications. Using blood as a window, one can study health and disease through this unique tool box with reactive biological fluids that mirrors the prevailing hemodynamics of the vessel walls and the various blood cell types. Many blood diseases, rare and common can and have been exploited using systems biology approaches with successful results and therefore ideal models for systems medicine. More importantly, hematopoiesis offers one of the best studied systems with insight into stem cell biology, cellular interaction, development; linage programing and reprograming that are every day influenced by the most mature and understood regulatory networks.

This issue of Hematology/Oncology Clinics of North America, guest edited by Drs. Bipin Savani and Mohamad Mohty, is devoted to Bone Marrow Transplantation. Articles in this issue include: Acute Myeloid Leukemia (AML); Acute Lymphoid Leukemia (ALL); Myelodysplastic Syndrome (AML); Myeloproliferative disorders (MPD); Chronic Lymphoid Leukemia; Chronic Myeloid Leukemia (CML); Multiple Myeloma and Amyloidosis; Non-Hodgkin Lymphoma (NHL); Hodgkin Lymphoma (HL); Severe Aplastic Anemia (SAA) and Paroxysmal Nocturnal Hemoglobinuria (PNH); Sickle Cell Anemia; Thalassemia; Benign immunodeficiency diseases; and Referral to transplant centers.

This issue of Hematology/Oncology Clinics, guest edited by Drs. Matthew Heeney and Alan Cohen, is devoted to Iron Disorders. Articles in this issue include: Hereditary Hemochromatosis (HFE and Non-HFE); Iron Refractory Iron Deficiency Anemia (IRIDA); Sideroblastic Anemia; Anemia of Chronic Disease/Inflammation; Pathophysiology of Transfusional Iron Overload; Transfusional Iron Overload and Iron Chelation Therapy; Iron Overload and its Management in Non-Transfusion-Dependent Thalassemia; Treatment of Iron Deficiency Anemia; and Iron Overload Assessment.

This issue of Hematology/Oncology Clinics, guest edited by Dr. Elliott Vichinsky, is devoted to Sickle Cell Disease, and focuses on pathophysiology of hemoglobinopathies, therapeutic targets, and new approaches to correcting ineffective erythropoiesis and iron dysregulation. Articles in this issue include Polymerization and red cell membrane changes; Overview on reperfusion injury in the pathophysiology of SCD; Regulation of ineffective erythropoiesis in iron metabolism; Altering oxygen affinity; Cellular adhesion and the endothelium; Arginine therapy; Role of the hemostatic system on SCD pathophysiology and potential therapeutics; Adenosine signaling and novel therapies; New approaches to correcting ineffective erythropoiesis and iron dysregulation; New approaches to correcting ineffective erythropoiesis and iron dysregulation; Fetal hemoglobin induction; Gene therapy for hemoglobinopathies; and Oxidative injury and the role of antioxidant therapy.

This issue of Emergency Medicine Clinics edited by Drs. John Perkins and and Jonathan Davis focuses on emergencies related to Hematology/Oncology and covers topics such as: Oncologic Mechanical Emergencies, Neutropenic Fever, Oncologic Metabolic Emergencies, Acute Leukemias, Pediatric Oncologic Emergencies, Chemotherapeutic Medications and their Emergent Complications, Anemia, Thrombotic Microangiopathies (TTP, HUS, HELLP), Congenital Bleeding Disorders, Acquired Bleeding Disorders and Antithrombotic agents, Sickle Cell Disease, and more!

This volume provides state-of-the-art techniques for studying various aspects of cholesterol homeostasis, including its uptake, synthesis and efflux from the cell, as well as its trafficking within the cell. Chapters also cover techniques for studying the regulation of cholesterol homeostasis at both the transcriptional and post-translational levels, as well as studying the membrane topology and structure of cholesterol-related proteins. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Cholesterol Homeostasis: Methods and Protocols aims to provide key techniques in tackling the investigation of cholesterol homeostasis.

This issue of Hematology/Oncology Clinics is focused on Hodgkin's Lymphoma and covers such topics as First HRS-cell line L428 and the detection of the CD-30 Antigen , "Normal" CD30-B-lymphocytes, CD-30-Antigen, Combination-Chemo-Radiotherapy, Early intensification (escBEACOPP), Customized/Targeted Therapy, and more.

This issue, focusing on Breast Cancer, includes topics such as: Radiation Therapy for DCIS, Axillary dissection, Pathology in the age of personalized breast cancer treatment:, Clinical implications for breast cancer subsets defined by molecular diagnostics, Management of CNS Metastases in Breast Cancer, Endocrine therapy for advanced breast cancer, Targeting the PI3K pathway in breast cancer, Treating the Older Breast Cancer Patient, Adjuvant chemotherapy in the age of targeted treatment, and Novel radiotherapy approaches for early breast cancer

Molecular pathology has significantly matured over the past decade to establish itself as a discipline in its own right. Patient diagnosis, prognosis, management and care have been influenced by molecular pathology testing algorithms on a global scale. Whether it pertains to carrier status of deleterious genes, diagnosis by molecular techniques, assessment of appropriate remission post treatment, parentage or forensics testing - molecular pathology continues to increase its presence and influence in the diagnostic laboratory armamentarium. Furthermore, intellectualization and proprietization of molecular pathology with respect to the discovery of new genes and or new techniques continues to pose new challenges of test ownership, legalities, liabilities, widespread acceptance and utility. This issue of Laboratory Clinics seeks to provide selective state of the art understanding of molecular pathology with respect to its relationship to key pathology disciplines as well as the current challenges and promise for the future

This issue focuses on Sarcoma in areas such as: Gastrointestinal Stromal Tumors: Risk assessment and adjuvant therapy, Gastrointestinal Stromal Tumors: Management of metastatic disease and emerging therapies, Liposarcoma, Leiomyosarcoma, Update in treatment and targets in cartilage and bone tumors, Update in treatment and targets in Ewing sarcoma, Angiosarcoma and Epithelioid Hemangioendothelioma, Emerging therapies for sarcoma, and Treatment of localized sarcomas.

This issue of Hematology/Oncology Clinics is guest edited by Dr. A. Koneti Rao and focuses on Disorder of the Platelets. Article titles include: Mechanisms of Platelet Activation and Inhibition, Testing Platelet Function, Clinical Implications of Platelet Genomics and Proteomics, Congenital Thrombocytopenias, Immune Thrombocytopenias, Heparin Induced Thrombocytopenia, and Functional defects: Chronic granulomatous disease (CGD) and beyond

Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of personalized cancer therapy is now growing rapidly, and the progress being made will result in significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. This book, written by acknowledged experts, discusses in detail the most recent developments in targeted cancer therapy using small molecules. A wide range of small molecules is covered, including, in addition to tyrosine kinase inhibitors, mTOR, proteasome, and multikinase inhibitors, among others. For each molecule, aspects such as chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed.

This issue focuses on three disease sections: Diabetes, Hematology and Coagulation, and covers diagnostic and management issues during pregnancy of selected topics in each section. The chapters cover new concepts, evolving management and important impacts on the mother and unborn child.

This issue of Hematology/Oncology Clinics is edited by Dr. Jennifer Brown and focuses on Chronic Lymphocytic Leukemia. Article topics include: What Have Recent Genomic Advances Taught us About CLL?, Biology of CLL in Different Microenvironments, What is the Significance of Stereotyped BCRs in CLL?, Understanding Immunodeficiency in CLL, MBL vs CLL: How Important is the Distinction?, Risk Stratification of CLL in 2012, Minimal Residual Disease Measurement in CLL, The BTK Inhibitor PCI-32765 in CLL, and Evolving Role of Stem Cell Transplantation in CLL

This issue of Hematology/Oncology Clinics is guest edited by Dr. Christoph Klein and focuses on the topic of Neutropenia. Article titles include: Homeostasis and migration of neutrophil granulocytes, Granulocyte-colony Stimulating Factor (G-CSF) receptor signaling, New Granulocyte-colony Stimulating Factor (G-CSF) Receptor Signaling Pathways, Neutrophil elastase (ELANE) - Genetics and Pathophysiology, Autosomal recessive variants of Severe congenital neutropenia (SCN), Leukocyte Adhesion Deficiency (LAD), and Genotype-phenotype correlations in Severe congenital neutropenia (S

2014 BMA Medical Book Awards Highly Commended in Internal Medicine category! This textbook on haematology in the Illustrated Colour Text series is suitable for medical students, junior doctors and others needing a concise and practical introduction to the subject. Concise and manageable coverage of the major blood diseases and their treatment. Does not overload the reader with science, unlike some competing books. Focus is on the haematology patient and on the practical aspects of the subject. Makes use of the attractive features of the ICT series - double page spreads, lots of colour illustrations, summary boxes. Updating to take account of recenty developments in stem cell biology. Increased emphasis on genomic and proteomic techniques in the diagnosis of haematological malignancy. Use of new imaging techniques including MRI and PET. Description of advances in treatment of leukaemia and lymphoma and in diagnosis and management of patients with thrombophilia and venous thrombosis. Development of new antimicrobial agents in management of immunosuppressed patients with infection. New double page spread on palliative care of patients with blood disorders. New illustrations.

Typically, manuals of pediatric hematology-oncology are written by specialists from high-income countries, and usually target an audience with a sub-specialist level of training, often assisted by cutting-edge diagnostic and treatment facilities. However, approximately 80% of new cases of cancer in children appear in mid- and low-income countries. Almost invariably, general practitioners or general pediatricians without special training in oncology will look after children with malignancies who enter the health care system in these countries. The diagnostic facilities are usually limited, as are the treatment options. The survival figures in these conditions are somewhere below 20%, while in high-income countries they are in the range of 80% for many childhood cancers. Pediatric Hematology-Oncology in Countries with Limited Resources is the only book of its kind to provide specific guidance applicable to limited resource settings and builds up from the foundation of general practitioner or general pediatrician competence. Written and edited by leaders in the field, this manual educates physicians on the essential components of the discipline, filtered through the experience of specialists from developing countries, with immediate applicability in the specific healthcare environment in these countries.

Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies in MPNs; Role of novel mutations in MPN pathogenesis and outcome; Role of JAK inhibitors in MPN treatment; Animal Models of MPNs; and Role of Germline Genetic Factors in MPN Pathogenesis.

Topics include: A Critical re-appraisal of Factor VIIa; Thrombocytopenia: Hit vs non-HIT causes; Transfusion Reactions: Newer concepts on the pathophysiology, incidence, treatment and prevention of TRALI; The utility of diagnostic scoring systems for DIC; Newer anticoagulants; Anemia in the ICU; The role of plasmapheresis in critical illness; The use of erythropoiesis stimulating agents in the ICU; and Coagulopathy in the ICU: DIC vs Liver disease. Is this distinction important?

Topics in this issue?include: Targeting IGF-1R; Tyrosine Kinase Inhibitors in Lung Cancer; Targeting mTOR; Targeting Hedgehog; Mitotic Inhibitors; Topoisomerase I Inhibitors; and New Strategies and Drugs Inhibiting Folate Pathways.

Topics for this issue will include: CLL: ? A Historical Perspective; Incidence & Epidemiology; Biology, Molecular Biology & Cytogenetics of CLL; What does the status of smatic hypermutations in IGVH genes tell us about the origin of CLL?; What does the status of ZAP-70 tell us about the biology of CLL?; and Approach to initial therapy: When to start therapy?